Surgery for Early-Stage Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude patients who are on adjuvant chemotherapy or Tamoxifen.
Is wide local excision (WLE) surgery safe for early-stage breast cancer?
Wide local excision (WLE) surgery is generally considered safe for early-stage breast cancer. Studies have shown that cancers can be safely removed using this method, and it has a low rate of needing additional surgery. Additionally, the choice of surgical approach does not significantly impact patients' body image satisfaction.12345
How does the treatment Wide Excision differ from other treatments for early-stage breast cancer?
Wide Excision (WLE) is a breast-conserving surgery that removes the cancerous tissue with a margin of healthy tissue around it, aiming to preserve as much of the breast as possible. Unlike mastectomy, which removes the entire breast, WLE focuses on maintaining breast appearance, although the optimal margin size for excision is still debated among surgeons.24567
What data supports the effectiveness of the treatment Wide Excision, Wide Local Excision, WLE for early-stage breast cancer?
Research suggests that wide local excision (WLE) is a popular conservative approach for small breast tumors, and it does not negatively impact body image or quality of life compared to other surgical methods. Additionally, WLE is associated with good cosmetic outcomes, which is important for patients' psychological well-being.23478
Who Is on the Research Team?
Julia Wong, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for individuals with small, low-grade ductal carcinoma in situ (DCIS) of the breast, measuring less than or equal to 2.5 cm. Participants must have had a recent high-quality mammogram and undergone surgical removal with clear margins of at least 1 cm. They should not have invasive cancer, previous breast cancers, nipple discharge, or be on certain cancer treatments like chemotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo wide excision surgery for DCIS without radiotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment through physical examinations and mammography
What Are the Treatments Tested in This Trial?
Interventions
- Wide Excision
Wide Excision is already approved in European Union, United States, Canada for the following indications:
- Invasive cutaneous melanoma
- Invasive cutaneous melanoma
- Invasive cutaneous melanoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Brigham and Women's Hospital
Collaborator
Massachusetts General Hospital
Collaborator
Beth Israel Deaconess Medical Center
Collaborator